全文获取类型
收费全文 | 14052篇 |
免费 | 1191篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 171篇 |
儿科学 | 341篇 |
妇产科学 | 322篇 |
基础医学 | 2179篇 |
口腔科学 | 305篇 |
临床医学 | 1496篇 |
内科学 | 3107篇 |
皮肤病学 | 136篇 |
神经病学 | 1128篇 |
特种医学 | 560篇 |
外科学 | 1705篇 |
综合类 | 188篇 |
一般理论 | 8篇 |
预防医学 | 1664篇 |
眼科学 | 142篇 |
药学 | 956篇 |
中国医学 | 7篇 |
肿瘤学 | 840篇 |
出版年
2022年 | 96篇 |
2021年 | 207篇 |
2020年 | 149篇 |
2019年 | 213篇 |
2018年 | 244篇 |
2017年 | 172篇 |
2016年 | 226篇 |
2015年 | 249篇 |
2014年 | 374篇 |
2013年 | 487篇 |
2012年 | 696篇 |
2011年 | 760篇 |
2010年 | 438篇 |
2009年 | 398篇 |
2008年 | 735篇 |
2007年 | 705篇 |
2006年 | 653篇 |
2005年 | 659篇 |
2004年 | 564篇 |
2003年 | 550篇 |
2002年 | 522篇 |
2001年 | 366篇 |
2000年 | 354篇 |
1999年 | 335篇 |
1998年 | 169篇 |
1997年 | 134篇 |
1996年 | 147篇 |
1995年 | 128篇 |
1994年 | 101篇 |
1992年 | 288篇 |
1991年 | 271篇 |
1990年 | 267篇 |
1989年 | 239篇 |
1988年 | 230篇 |
1987年 | 195篇 |
1986年 | 235篇 |
1985年 | 208篇 |
1984年 | 200篇 |
1983年 | 186篇 |
1982年 | 135篇 |
1981年 | 120篇 |
1980年 | 105篇 |
1979年 | 169篇 |
1978年 | 135篇 |
1977年 | 117篇 |
1976年 | 97篇 |
1974年 | 129篇 |
1973年 | 115篇 |
1972年 | 103篇 |
1968年 | 96篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
3.
4.
5.
Uptake of Adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas 总被引:1,自引:0,他引:1
H. von Holst E. Knochenhauer H. Blomgren V. P. Collins L. Ehn M. Lindquist G. Norén C. Peterson 《Acta neurochirurgica》1990,104(1-2):13-16
Summary Eight patients with malignant gliomas verified on CT scan, received an intravenous injection of 50 mg of Adriamycin R, 24 hours prior to surgical removal of the tumour. Peroperatively, both tumour and surrounding tissue specimens were obtained for determination of the tissue concentrations of Adriamycin and its reduced metabolite Adriamycinol. It was found that Adriamycin could be detected in tumour tissue from all patients. The concentration varied between 0,9 and 4,6 nmol/g tissue. In contrast, Adriamycin could only be detected in surrounding brain tissue from one patient.In anin vitro study a human malignant glioma cell line (U-251 MG) was exposed to various concentrations of Adriamycin for 24 hours. It was found that an intracellular drug concentration above 30 nmol/g cells caused a concentration dependent inhibition of cell growth. Thus, it is likely that the poor effect of Adriamycin on patients with malignant gliomas is due to an ineffective drug accumulation in the tumour tissue. 相似文献
6.
Dr. Michael Gosland Pharm.D. Dr. Bert Lum Pharm.D. Dr. Julia Schimmelpfennig Pharm.D. Dr. James Baker Pharm.D. Dr Michael Doukas M.D. 《Pharmacotherapy》1996,16(1):16-39
Cisplatin in combination with other cytotoxic agents is the backbone for a potential cure of testicular germ cell neoplasms and is a critical factor in the substantial activity observed in the treatment of small cell lung cancer, bladder cancer, and ovarian germ cell tumors. Resistance to cisplatin at the onset of treatment or at relapse limits its curative potential, however. Laboratory studies using both cells selected for cisplatin resistance by exposure to sublethal concentrations and biopsy specimens from patients' tumors provide insights for the potential mechanisms of resistance. The mechanisms identified in vitro include a complex and wide array of related and unrelated pathways such as alterations in cellular drug transport, enhanced DNA repair dependent and independent of signal transduction pathways, and enhanced intracellular detoxification such as glutathione and metallothionein systems. Studies of these mechanisms have identified a number of agents with known potential for administration to humans and that reverse cisplatin resistance in vitro; for example, reversal of cellular accumulation defects by dipyridamole; inhibition of DNA repair by hydroxyurea, pentoxifylline, and novobiocin; inhibition of the glutathione system by ethacrynic acid and buthionine sulfoximine; and inhibition of signal transduction pathways by cyclosporine, tamoxifen, and calcium channel-blocking agents. Current phase I clinical trials are focusing on the most effective doses and schedules to administer these agents in combination with cisplatin. Initial uncontrolled trials in limited numbers of patients suggest that the addition of modulators of cisplatin has the potential to reverse resistance in patients previously failing therapy. Another promising avenue for circumventing cisplatin resistance is the development of noncross-resistant platinum analogs. 相似文献
7.
8.
K W Anquist S Panchanathan P C Rowe R G Peterson A Sirnick 《Canadian Medical Association journal》1991,145(8):965-968
OBJECTIVE: To determine whether the use of dimenhydrinate was associated with delay in the diagnosis and management of treatable illnesses or with direct adverse effects in children with vomiting presenting to an emergency department. DESIGN: Questionnaire survey and review of drug reaction and telephone inquiry records. SETTING: The emergency department of a tertiary care children's hospital and a provincial poison information centre. PATIENTS: The parents of 148 children who presented with vomiting completed the questionnaire. The database at the poison information centre included 474 reports of adverse drug reactions over an 8-year period and 105 reports of telephone inquiries over a 4-year period. MAIN RESULTS: Twenty-one (14%) of 148 children had received dimenhydrinate before arrival at the emergency department. The patients who had received dimenhydrinate were more likely than the others to present more than 12 hours after the onset of vomiting (14 [67%] of 21 v. 43 [34%] of 127, p less than 0.01). The discharge diagnoses for those who had received dimenhydrinate included asthma, pelvic inflammatory disease and urinary tract infection. No clinically important direct adverse reactions to dimenhydrinate were documented. CONCLUSIONS: The use of dimenhydrinate in children with vomiting is associated with a risk of delay in the diagnosis of treatable medical conditions. 相似文献
9.
10.